solute carrier family 6 member 19Genealiases: B0AT1 · HND
Q-omics provides the consensus-scored SLC6A19 profile across patient tissues and cancer cell-line models. SLC6A19 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC6A19 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SLC6A19 RNA expression shows 11,632 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where SLC6A19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A19 survival associations across molecular data types. SLC6A19 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A19 RNA expression–survival associations across cancer types. High SLC6A19 expression shows unfavorable associations in LUAD, UCEC, MESO and LIHC, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC6A19 RNA expression.
This table summarizes SLC6A19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC6A19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A19 shows lower tumor expression in KIRC, KIRP, COAD, KICH and LIHC and higher tumor expression in HNSC. The KIRC box plot shows higher SLC6A19 RNA expression in normal versus tumor tissue (log2 FC = −3.171, t-test p < 0.001).
This table shows molecular features associated with SLC6A19 in patient tissues and cancer cell lines. In patient samples, SLC6A19 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC6A19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
